Analysts expect Paratek Pharmaceuticals Inc (NASDAQ:PRTK) to post earnings of ($0.89) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Paratek Pharmaceuticals’ earnings, with estimates ranging from ($1.05) to ($0.55). Paratek Pharmaceuticals posted earnings per share of ($0.77) during the same quarter last year, which indicates a negative year over year growth rate of 15.6%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, November 14th.
According to Zacks, analysts expect that Paratek Pharmaceuticals will report full-year earnings of ($3.41) per share for the current fiscal year, with EPS estimates ranging from ($3.91) to ($1.69). For the next fiscal year, analysts forecast that the business will post earnings of ($3.26) per share, with EPS estimates ranging from ($4.11) to ($2.22). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that cover Paratek Pharmaceuticals.
Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.92) by ($0.02). The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.10 million. Paratek Pharmaceuticals had a negative net margin of 1,961.41% and a negative return on equity of 106.39%.
A number of analysts have commented on the stock. Zacks Investment Research cut shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, August 3rd. Cantor Fitzgerald set a $50.00 price objective on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, June 11th. Bank of America initiated coverage on shares of Paratek Pharmaceuticals in a research report on Monday, August 27th. They set a “neutral” rating and a $13.00 price objective on the stock. Finally, Wedbush set a $20.00 price objective on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 9th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $33.75.
In other news, VP William M. Haskel sold 7,323 shares of the stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $9.97, for a total transaction of $73,010.31. Following the transaction, the vice president now owns 62,274 shares of the company’s stock, valued at approximately $620,871.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Michael Bigham sold 22,500 shares of the stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $9.97, for a total transaction of $224,325.00. Following the transaction, the chairman now directly owns 177,230 shares in the company, valued at approximately $1,766,983.10. The disclosure for this sale can be found here. Insiders have sold a total of 41,823 shares of company stock worth $416,975 in the last three months. Insiders own 6.20% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in PRTK. Balter Liquid Alternatives LLC bought a new position in Paratek Pharmaceuticals in the 2nd quarter valued at about $137,000. Wedbush Securities Inc. bought a new position in Paratek Pharmaceuticals in the 1st quarter valued at about $144,000. Cubist Systematic Strategies LLC bought a new position in Paratek Pharmaceuticals in the 1st quarter valued at about $147,000. Metropolitan Life Insurance Co. NY lifted its position in Paratek Pharmaceuticals by 81.4% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the specialty pharmaceutical company’s stock valued at $151,000 after acquiring an additional 6,625 shares in the last quarter. Finally, Clear Harbor Asset Management LLC bought a new position in Paratek Pharmaceuticals in the 2nd quarter valued at about $154,000. 77.31% of the stock is currently owned by institutional investors.
PRTK traded down $0.03 during trading on Monday, reaching $10.08. 363,304 shares of the stock traded hands, compared to its average volume of 429,821. The company has a current ratio of 7.88, a quick ratio of 7.88 and a debt-to-equity ratio of 2.37. The stock has a market capitalization of $320.47 million, a P/E ratio of -3.05 and a beta of 0.65. Paratek Pharmaceuticals has a 12 month low of $9.38 and a 12 month high of $28.09.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Recommended Story: Short Selling Stocks and Day Traders
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.